Meeting
2015 ASCO Annual Meeting
Determining viability of using APNG status as a prognostic marker in patients with glioblastoma multiforme.
Authors
Rikke Hedegaard Dahlrot
Department of Oncology, Odense University Hospital, Odense, Denmark
Rikke Hedegaard Dahlrot , Sofie Hellwege , Sigurd Fosmark , Kristian Lindstroem Jensen , Jesper Lohse , Helene Derand , Jacob Hjelmborg , Steinbjorn Hansen , Bjarne Winther Kristensen
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Central Nervous System Tumors
Track
Central Nervous System Tumors
Sub Track
Central Nervous System Tumors
Citation
J Clin Oncol 33, 2015 (suppl; abstr 2028)
DOI
10.1200/jco.2015.33.15_suppl.2028
Abstract #
2028
Poster Bd #
17
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Annual Meeting
Final results of phase 2 trial of personal dendritic cell (DC) vaccines loaded with autologous tumor antigens (ATA) in newly diagnosed glioblastoma (GBM).
First Author: Daniela Annenelie Bota
Poster
2019 ASCO Annual Meeting
A TITE-CRM phase I/II study of disulfiram and copper with concurrent radiation therapy and temozolomide for newly diagnosed glioblastoma.
First Author: Jiayi Huang
Poster
2014 ASCO Annual Meeting
MGMT promoter methylation as a prognostic biomarker for benefit from dose-intensified temozolomide rechallenge in progressive glioblastoma: First results from the randomized phase II DIRECTOR trial.
First Author: Ghazaleh Tabatabai
Poster
2013 ASCO Annual Meeting
Efficacy and safety of radiotherapy (RT) plus temozolomide (TMZ) in elderly patients (EP) with glioblastoma (GBM).
First Author: Giuseppe Lombardi